Examples of Epanova in a sentence
Epanova was developed by Omthera Pharmaceuticals, Inc., and is now owned by AstraZeneca Pharmaceuticals LP (AstraZeneca).
At one year the rate of patients in remission was 59% in the treated group and 26% receiving placebo (p = 0.03).163 Two phase III studies (EPIC-1 and EPIC-2) with a similar enteric release formulation of omega-3 fatty acids (Epanova) are expected to report in 2006.
Neither Epanova nor Omtryg have been commercially launched, but could launch at any time.
The study is a randomized, double-blind, placebo-controlled (corn oil), parallel group design that is believed to have enrolled approximately 13,000 patients with hypertriglyceridemia and low HDL and high risk for cardiovascular disease randomized 1:1 to either corn oil plus statin or Epanova plus statin, once daily, for approximately 3-5 years as determined when the number of major adverse cardiovascular event outcomes is reached.
The complaint alleged infringement of the patent arising from the expected launch of Epanova, a product that is expected to compete with Vascepa in the United States.
In 2012, Omthera reported positive results from two Phase III trials (EVOLVE and ESPRIT) examining the effectiveness of Epanova in lowering very high triglycerides, and in reducing non-HDL cholesterol in combination with a statin for patients with high triglycerides.
GlaxoSmithKline's (NYSE: GSK ) drug Lovaza, Amarin s Vascepa and AstraZeneca s Epanova, made up of omega-3 fatty acid similar to Bezalip SR, compete for share of this growing dyslipidemia subpopulation.
A year ago, there were four primary areas of concern expressed to us by investors; one, FDA approval of an expanded VASCEPA label [sic]; two, competition from Epanova; three, accuracy of our financial resources; and four, results of end of litigation [sic].
STRENGTH was a large-scale, global CVOT designed to evaluate the safety and efficacy of Epanova compared to placebo, both in combination with SoC statin medicines.
AstraZeneca intends to pursue a large-scale cardiovascular outcomes trial for Epanova in combination with statins.Pascal Soriot, Chief Executive Officer of AstraZeneca said: “The number of people with elevated triglyceride levels is rising rapidly across the world, due in part to the increasing prevalence of obesity and diabetes.